Longeveron Believes Cash and Cash Equivalents Will Fund Oper Expenses and Cap Expenditure Requirements Into 4Q
Longeveron Believes Cash and Cash Equivalents Will Fund Oper Expenses and Cap Expenditure Requirements Into 4Q
Longeveron: Phase 2b Clinical Trial Evaluating Lomecel-BTM in Rare Pediatric Disease HLHS on Track for Completing Enrollment by End of 2024 >LGVN
Longeveron: Phase 2b Clinical Trial Evaluating Lomecel-BTM in Rare Pediatric Disease HLHS on Track for Completing Enrollment by End of 2024 >LGVN
Longeveron 1Q Rev $548,000 >LGVN
Longeveron 1Q Rev $548,000 >LGVN
Longeveron Q1 EPS $(1.61) Beats $(2.00) Estimate, Sales $548.00K Beat $100.00K Estimate
Longeveron (NASDAQ:LGVN) reported quarterly losses of $(1.61) per share which beat the analyst consensus estimate of $(2.00) by 19.5 percent. This is a 27.15 percent increase over losses of $(2.21) pe
Earnings Flash (LGVN) LONGEVERON Posts Q1 Revenue $548,000
04:10 PM EDT, 05/14/2024 (MT Newswires) -- Earnings Flash (LGVN) LONGEVERON Posts Q1 Revenue $548,000
Longeveron | 10-Q: Quarterly report
Longeveron Board Reshuffle and Nasdaq Compliance Efforts
Longeveron Announces Board Transitions
Longeveron: Jeffrey Pfeffer and Cathy Ross Have Voluntarily Resigned From Bd >LGVN
Longeveron: Jeffrey Pfeffer and Cathy Ross Have Voluntarily Resigned From Bd >LGVN
Longeveron Appoints Former Merck Exec Richard Kender to Board >LGVN
Longeveron Appoints Former Merck Exec Richard Kender to Board >LGVN
Longeveron Granted U.S. Patent #11975068: Mesenchymal Stem Cells as Vaccine Adjuvants and Methods for Using the Same
Longeveron Granted U.S. Patent #11975068: Mesenchymal Stem Cells as Vaccine Adjuvants and Methods for Using the Same
Longeverion Granted Israeli Patent Titled 'METHODS OF USING HUMAN MESENCHYMAL STEM CELLS TO EFFECT CELLULAR AND HUMORAL IMMUNITY'
Longeverion Granted Israeli Patent Titled 'METHODS OF USING HUMAN MESENCHYMAL STEM CELLS TO EFFECT CELLULAR AND HUMORAL IMMUNITY'
Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will report first quarter 2024 financial results
Longeveron Files Prospectus for Secondary Offering
Longeveron (LGVN) on Tuesday filed a preliminary prospectus for resale of about five million class A common shares by selling stockholders. The company said it will not get any of the proceeds from th
Longeveron Is Maintained at Buy by HC Wainwright & Co.
Longeveron Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : The Longeveron (LGVN.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $6.00 to $12.00.
HC Wainwright & Co. : The Longeveron (LGVN.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $6.00 to $12.00.
HC Wainwright & Co. Maintains Buy on Longeveron, Adjusts Price Target To $12
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Longeveron (NASDAQ:LGVN) with a Buy, adjusts target to $12 from $6.
Longeveron Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/29/2024 574.16% HC Wainwright & Co. $6 → $12 Maintains Buy 12/04/2023 237.08% HC Wainwright & Co. → $6
Analysts' Top Healthcare Picks: Longeveron (LGVN), Optinose (OPTN)
Longeveron to Present at the Planet MicroCap Showcase
No Data